Synnovis
Life-saving genetic test for every baby in England rolls out from October 2026
The rapid digital PCR test for Spinal Muscular Atrophy (SMA) developed by Synnovis* is a first for England
SYNLAB is delighted to recognise the Synnovis Monogenics team, based at Guy’s Hospital in London, for their contribution to making the addition of Spinal Muscular Atrophy (SMA) testing to England’s newborn screening programme possible.
Our team developed England’s first rapid digital PCR test for SMA which delivers results in under 24 hours, compared to the 14-day national standard. For when every hour matters, this test is a major step forward for patients and families affected by this rare but serious genetic condition.
SMA is a severe, progressive neuromuscular disorder where patients present as “floppy infants” with early onset of muscle weakness. In the most severe cases, prospects of survival are limited unless life saving treatment is delivered early on.
Until now, the challenge for newborn screening programmes was not only to identify affected babies but to deliver confirmatory test results swiftly so that treatment decisions can be made without delay.
Dominic Harrington, Chief Scientific Officer, SYNLAB UK&I, said: “By developing a rapid digital PCR test for SMA last year, the Synnovis Monogenics team have turned scientific innovation into a practical pathway that improves lives.
“The introduction of SMA testing for newborns across England is a great example of the vital role our scientists play in translating promising research into real patient benefit.”
The Synnovis team’s work was celebrated at the 2026 Royal College of Pathologists Achievement Awards, with a Highly Commended in the Team Award for Innovation, Technology or Development of AI category.
Last week’s announcement further recognises the important contribution of diagnostic scientists and laboratory teams in healthcare advancements.